Liquid Chromatography-Tandem Mass Spectrometry Method for Ticagrelor and its Active Metabolite Determination in Human Plasma: Application to a Pharmacokinetic Study

Author(s): Niloufar Marsousi, Serge Rudaz, Jules A. Desmeules, Youssef Daali*

Journal Name: Current Analytical Chemistry

Volume 16 , Issue 5 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Ticagrelor is a highly recommended new antiplatelet agent for the treatment of patients with acute coronary syndrome at moderate or high ischemic risk. There is a real need for rapid and accurate analytical methods for ticagrelor determination in biological fluids for pharmacokinetic studies. In this study, a sensitive and specific LC-MS method was developed and validated for quantification of ticagrelor and its Active Metabolite (AM) in human plasma over expected clinical concentrations.

Methods: Samples were handled by Liquid-Liquid Extraction (LLE). A linear gradient was applied with a mobile phase composed of formic acid 0.1% and acetonitrile with 0.1% of formic acid using a C18 reversed-phase column. MS spectra were obtained by electrospray ionization in negative mode and optimized at 521.4→360.9 m/z, 477.2→361.2 m/z and 528.1→367.9 m/z transitions for ticagrelor, AM and ticagrelor-d7, respectively.

Results: This method allowed rapid elution, in less than 4 minutes, and quantification of concentrations as low as 2 ng/mL for ticagrelor and 1 ng/mL for AM using only 100 μL of human plasma. LLE using hexane/ethyl acetate (50/50) was an optimal compromise in terms of extraction recovery and endogenous compounds interference. Trueness values of 87.8% and 89.5% and precisions of 84.1% and 93.8% were obtained for ticagrelor and AM, respectively. Finally, the usefulness of the method was assessed in a clinical trial where a single 180 mg ticagrelor was orally administered to healthy male volunteers. Pharmacokinetic parameters of ticagrelor and its active metabolite were successfully determined.

Conclusion: A sensitive and specific quantification LC-MS-MS method was developed and validated for ticagrelor and its active metabolite determination in human plasma. The method was successfully applied to a clinical trial where a single ticagrelor 180 mg dose was orally administered to healthy male volunteers. The described method allows quantification of concentrations as low as 2 ng/mL of ticagrelor and 1 ng/mL of the metabolite using only 100 μL of plasma.

Keywords: Biological matrix, human plasma, LC-MS/MS, pharmacokinetic study, quantification, ticagrelor.

[1]
Roffi, M.; Patrono, C.; Collet, J.P.; Mueller, C.; Valgimigli, M.; Andreotti, F.; Bax, J.J.; Borger, M.A.; Brotons, C.; Chew, D.P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J., 2015, 2015
[PMID: 26320110]
[2]
Steg, P.G.; James, S.K.; Atar, D.; Badano, L.P.; Blömstrom-Lundqvist, C.; Borger, M.A.; Di Mario, C.; Dickstein, K.; Ducrocq, G.; Fernandez-Aviles, F.; Gershlick, A.H.; Giannuzzi, P.; Halvorsen, S.; Huber, K.; Juni, P.; Kastrati, A.; Knuuti, J.; Lenzen, M.J.; Mahaffey, K.W.; Valgimigli, M.; van ’t Hof, A.; Widimsky, P.; Zahger, D. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., 2012, 33(20), 2569-2619.
[http://dx.doi.org/10.1093/eurheartj/ehs215] [PMID: 22922416]
[3]
Serebruany, V.L. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am. Heart J., 2011, 161(1), 1-4.
[http://dx.doi.org/10.1016/j.ahj.2010.09.017] [PMID: 21167333]
[4]
Teng, R.; Oliver, S.; Hayes, M.A.; Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos., 2010, 38(9), 1514-1521.
[http://dx.doi.org/10.1124/dmd.110.032250] [PMID: 20551239]
[5]
Zhou, D.; Andersson, T.B.; Grimm, S.W. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab. Dispos., 2011, 39(4), 703-710.
[http://dx.doi.org/10.1124/dmd.110.037143] [PMID: 21177984]
[6]
Sillén, H.; Cook, M.; Davis, P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2011, 879(23), 2315-2322.
[http://dx.doi.org/10.1016/j.jchromb.2011.06.023] [PMID: 21727045]
[7]
Xu, X.; Ding, X.; Yuan, B.; Li, W.; Wang, Y.; Jin, Y.; Xu, H. Validated liquid chromatography-tandem mass spectrometry method for quantification of ticagrelor and its active metabolite in human plasma. Biomed. Chromatogr., 2019, 33(6)e4498
[http://dx.doi.org/10.1002/bmc.4498] [PMID: 30675914]
[8]
Zhong, W.; Wang, X.; Tang, L.; Mai, L.; Chen, X.P.; He, G.; Zheng, Z.; Zhong, S. Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. J. Anal. Toxicol., 2016, 40(6), 445-453.
[http://dx.doi.org/10.1093/jat/bkw039] [PMID: 27165805]
[9]
Sillén, H.; Cook, M.; Davis, P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(25), 2299-2306.
[http://dx.doi.org/10.1016/j.jchromb.2010.06.018] [PMID: 20688583]
[12]
Teng, R.; Mitchell, P.; Butler, K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur. J. Clin. Pharmacol., 2013, 69(4), 877-883.
[http://dx.doi.org/10.1007/s00228-012-1436-x] [PMID: 23093043]
[13]
Teng, R.; Butler, K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur. J. Clin. Pharmacol., 2013, 69(10), 1801-1808.
[http://dx.doi.org/10.1007/s00228-013-1543-3] [PMID: 23748750]
[14]
Holmberg, M.T.; Tornio, A.; Joutsi-Korhonen, L.; Neuvonen, M.; Neuvonen, P.J.; Lassila, R.; Niemi, M.; Backman, J.T. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br. J. Clin. Pharmacol., 2013, 75(6), 1488-1496.
[http://dx.doi.org/10.1111/bcp.12026] [PMID: 23126367]
[15]
Butler, K.; Teng, R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br. J. Clin. Pharmacol., 2010, 70(1), 65-77.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03669.x] [PMID: 20642549]
[16]
Marsousi, N.; Samer, C.F.; Fontana, P.; Reny, J.L.; Rudaz, S.; Desmeules, J.A.; Daali, Y. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin. Pharmacol. Ther., 2016, 100(3), 295-304.
[http://dx.doi.org/10.1002/cpt.407] [PMID: 27264793]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2020
Page: [602 - 608]
Pages: 7
DOI: 10.2174/1573411015666190220144904
Price: $65

Article Metrics

PDF: 14
HTML: 2
EPUB: 1